Abstract. The aim of the present study was to investigate the role of estrogen receptor (ER) β in the prognosis of ERα-positive breast cancer in postmenopausal women, and its effect on the efficacy of endocrine therapy. Tissue specimens from 195 patients with postmenopausal breast cancer were analyzed. ERβ expression levels were detected using immunohistochemical staining. Kaplan-Meier analysis was performed to assess patient survival, and the difference in survival was analyzed using the log-rank test. Cox regression was utilized to evaluate prognostic factors. The results revealed that the disease-free survival rate decreased dramatically as ERβ expression levels increased in all postmenopausal ERα-positive breast cancer patients, and ERβ expression was identified to be an indicator of poor prognosis in cases of this disease. Similarly, in postmenopausal ERα-positive breast cancer patients undergoing endocrine therapy, high ERβ expression levels reduced the disease-free survival rate and were correlated with poor patient prognosis. However, in such patients who were not treated with endocrine therapy, disease-free survival rate and prognosis were not significantly affected by ERβ expression. In conclusion, ERβ overexpression led to endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients, suggesting that ERβ may affect breast cancer prognosis via an increase in endocrine therapy resistance.
Abstract. Behçet's disease (BD) is a multi-system inflammatory condition with unknown cause, characterized by a triple-symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis and skin lesions. It predominantly affects people living around the Mediterranean basin and in Japan. The effects of the major histocompatibility complex class I chain related gene A (MICA) A6 allele on susceptibility to Behçet's disease (BD) have been reported previously, however, their results have been unreliable. The present study aimed to determine whether an association between the MICA-A6 allele and BD susceptibility exists. A total of 12 case-control studies, examining the association between MICA-A6 and BD and involving 752 cases and 1,175 controls were included in the present meta-analysis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The results of meta-analysis revealed that the frequency of the MICA-A6 allele in the case group was significantly higher than those in the control groups (P<0.001, OR=2.43, 95% CI: 1.99-2.97). Sub-group analysis by ethnicity indicated that the association between of MICA-A6 gene to BD remained in Asian populations (5 cases and 731 controls) and Caucasian populations (242 cases and 444 controls) with OR=2.65, 95% CI: 2.07-3.38 and OR=2.23, 95% CI: 1.37-3.62, respectively. These findings demonstrate that MICA-A6 gene is associated with susceptibility to BD. The MICA-A6 gene may serve as an early diagnostic marker for BD in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.